STS/SCA: How to Achieve a 0% Transfusion Rate after CABG

All of the relevant financial relationships listed for these individuals have been mitigated. Unless otherwise noted, speakers have nothing to disclose.

Moderators

Andrew Shaw, MD
Disclosure(s): Alexion: Advisory Board (Ongoing); Novartis: Advisory Board (Ongoing); NxStage: Advisory Board (Ongoing); Retia: Advisory Board (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)

Wanda Popescu, MD

Presentations

  1. How Much Are We Transfusing: The Cardiac Surgery Transfusion Landscape
    Subhasis Chatterjee, MD
    Disclosure(s): Eagle Pharmaceutcials: Advisory Board (Terminated, March 10, 2022)
     
  2. How We Achieved a 10% CABG Transfusion Rate
    Rawn Salenger, MD
    Disclosure(s): Atricure: Advisory Board (Ongoing); Edwards LifeSciences: Advisory Board (Terminated, November 1, 2022); Encare: Consultant (Ongoing); La Jolla: Advisory Board (Terminated, April 15, 2023); Society for the Advancement of Patient Blood Management: Co-lead of expert consensus project on surgical bleeding (Ongoing); Terumo: Consultant (Terminated, July 31, 2022); Zimmer Biomet: Advisory Board (Ongoing)
     
  3. Anemic or Iron Deficient Patient Going In? We Have a Solution
    Vicki Morton-Bailey, DNP, AGNP-BC
    Disclosure(s): Edwards Lifesciences: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)
     
  4. Use of Factor VIII Inhibitor Bypassing Activity versus Fresh Frozen Plasma as First Line Therapy for Post-Cardiopulmonary Bypass Coagulopathy
    Hyungjoo Kim, MD Candidate
     
  5. Association between Preoperative Anemia and Intraoperative Transfusions with Operative Outcomes of Isolated CABG: Analysis of the National STS Adult Cardiac Surgery Database
    Motahar Hosseini, MD
     
  6. Invited Discussant
    Susan Moffat-Bruce, MD, PhD, MBA
     
  7. The Perfusionist's Role to Reduce Transfusions
    Cory M. Alwardt, PhD, CCP
    Disclosure(s): LivaNova: Consultant (Terminated, June 8, 2023)
     
  8. Achieving Program Consensus on Transfusion Algorithms
    Jenny Kwak, MD, FASE, FASA
Activity summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Participation
Activity opens: 
02/01/2024
Activity expires: 
02/15/2027
Cost:
$0.00
Part of: 
2024 STS Annual Meeting Online: Critical Care and Perioperative Management Track
Rating: 
0

Available Credit

  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Participation

Price

Cost:
$0.00
Please login or register to take this course.

All of the relevant financial relationships listed for these individuals have been mitigated. Unless otherwise noted, speakers have nothing to disclose.

Moderators

Andrew Shaw, MD
Disclosure(s): Alexion: Advisory Board (Ongoing); Novartis: Advisory Board (Ongoing); NxStage: Advisory Board (Ongoing); Retia: Advisory Board (Ongoing), Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)

Wanda Popescu, MD

Presentations

  1. How Much Are We Transfusing: The Cardiac Surgery Transfusion Landscape
    Subhasis Chatterjee, MD
    Disclosure(s): Eagle Pharmaceutcials: Advisory Board (Terminated, March 10, 2022)
     
  2. How We Achieved a 10% CABG Transfusion Rate
    Rawn Salenger, MD
    Disclosure(s): Atricure: Advisory Board (Ongoing); Edwards LifeSciences: Advisory Board (Terminated, November 1, 2022); Encare: Consultant (Ongoing); La Jolla: Advisory Board (Terminated, April 15, 2023); Society for the Advancement of Patient Blood Management: Co-lead of expert consensus project on surgical bleeding (Ongoing); Terumo: Consultant (Terminated, July 31, 2022); Zimmer Biomet: Advisory Board (Ongoing)
     
  3. Anemic or Iron Deficient Patient Going In? We Have a Solution
    Vicki Morton-Bailey, DNP, AGNP-BC
    Disclosure(s): Edwards Lifesciences: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing)
     
  4. Use of Factor VIII Inhibitor Bypassing Activity versus Fresh Frozen Plasma as First Line Therapy for Post-Cardiopulmonary Bypass Coagulopathy
    Hyungjoo Kim, MD Candidate
     
  5. Association between Preoperative Anemia and Intraoperative Transfusions with Operative Outcomes of Isolated CABG: Analysis of the National STS Adult Cardiac Surgery Database
    Motahar Hosseini, MD
     
  6. Invited Discussant
    Susan Moffat-Bruce, MD, PhD, MBA
     
  7. The Perfusionist's Role to Reduce Transfusions
    Cory M. Alwardt, PhD, CCP
    Disclosure(s): LivaNova: Consultant (Terminated, June 8, 2023)
     
  8. Achieving Program Consensus on Transfusion Algorithms
    Jenny Kwak, MD, FASE, FASA